Business Description
MetaVia Inc
NAICS : 325412
SIC : 2834
ISIN : US36870A1088
Description
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 140.71 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 82.2 | |||||
| 3-Year EPS without NRI Growth Rate | 80.9 | |||||
| 3-Year FCF Growth Rate | 76.2 | |||||
| 3-Year Book Growth Rate | -66.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 29.16 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.8 | |||||
| 9-Day RSI | 20.47 | |||||
| 14-Day RSI | 25.8 | |||||
| 6-1 Month Momentum % | -41.91 | |||||
| 12-1 Month Momentum % | -30.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.41 | |||||
| Quick Ratio | 2.41 | |||||
| Cash Ratio | 2.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -291.2 | |||||
| Shareholder Yield % | 0.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -172.89 | |||||
| ROA % | -118.39 | |||||
| ROIC % | -2161.53 | |||||
| ROC (Joel Greenblatt) % | -11143.92 | |||||
| ROCE % | -157.66 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.2 | |||||
| Price-to-Tangible-Book | 1.2 | |||||
| EV-to-EBIT | 0.23 | |||||
| EV-to-Forward-EBIT | -0.03 | |||||
| EV-to-EBITDA | 0.23 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 1.19 | |||||
| Price-to-Net-Cash | 1.21 | |||||
| Earnings Yield (Greenblatt) % | 434.78 | |||||
| FCF Yield % | -145.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MTVA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
MetaVia Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.77 | ||
| Beta | 0.28 | ||
| Volatility % | 100.67 | ||
| 14-Day RSI | 25.8 | ||
| 14-Day ATR ($) | 0.244477 | ||
| 20-Day SMA ($) | 2.192675 | ||
| 12-1 Month Momentum % | -30.5 | ||
| 52-Week Range ($) | 1.51 - 6.7499 | ||
| Shares Outstanding (Mil) | 8.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MetaVia Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MetaVia Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
MetaVia Inc Frequently Asked Questions
What is MetaVia Inc(MTVA)'s stock price today?
The current price of MTVA is $1.76. The 52 week high of MTVA is $6.75 and 52 week low is $1.51.
When is next earnings date of MetaVia Inc(MTVA)?
The next earnings date of MetaVia Inc(MTVA) is 2025-02-07 Est..
Does MetaVia Inc(MTVA) pay dividends? If so, how much?
MetaVia Inc(MTVA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers